Clinical Trial Highlights

Dr. Volker Diehl discusses two important trials; a US trial for frontline therapy, ECHELON and a GHSG lead trial with escalated BEACOPP.

Dr. Steidl discusses the significance of tumor-associated macrophages in classical Hodgkin lymphoma.

Dr. Engert discusses the HD15 trial that explores the quality assurance protocol for reduction of toxicity and the prognostic relevance of FDG-PET in patients with advanced stage Hodgkin lymphoma.
Results 1 - 3 of 3